JBF Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

JBF Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-20,000	Closed	-$1.89M	–	78
2014 Q2	$1.89M	Buy	+20,000	New	+$1.4M	0.28%	23

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JBF Capital's VRTX Position: Q3 2014 in Review

JBF Capital sold out of Vertex Pharmaceuticals (VRTX) in Q3 2014, closing a stake of 20,000 shares — an estimated $1.89M sold.

JBF Capital first reported a position in VRTX in Q2 2014 and held it in 1 quarter. The position peaked at $1.89M in Q2 2014. 431 funds tracked by Wall St. Rank hold VRTX as of Q3 2014.

JBF Capital reported no remaining Vertex Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
JBF Capital sold 20,000 Vertex Pharmaceuticals shares in Q3 2014, an estimated $1.89M.
JBF Capital first reported a position in Vertex Pharmaceuticals in Q2 2014 and held it in 1 quarter.
JBF Capital's Vertex Pharmaceuticals position peaked at $1.89M in Q2 2014.
431 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2014.

Based on JBF Capital's 13F filing for Q3 2014, filed 16 Oct 2014.